Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE - Midatech Pharma US Inc. | dara_ex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of report (Date of earliest event reported): April 1, 2013
_____________
DARA BioSciences, Inc.
(Exact name of registrant as specified in charter)
______________
|
Delaware
|
0-19410
|
04-3216862
|
||
|
(State or other jurisdiction
of incorporation)
|
(Commission
file number)
|
(IRS Employer
Identification Number)
|
8601 Six Forks Road, Suite 160, Raleigh, North Carolina 27615
(Address of principal executive offices)
919-872-5578
Registrant’s telephone number, including area code:
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions.
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02 Results of Operations and Financial Condition.
On April 1, 2013, DARA BioSciences, Inc. (the “Company”) issued a press release announcing certain financial results for the fiscal year ended December 31, 2012. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
The following exhibit is furnished herewith:
|
Exhibit No.
|
Exhibit Description
|
||
|
Press Release, dated April 1, 2013.
|
|||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
DARA BioSciences, Inc.
|
|||
|
Date: April 1, 2013
|
By:
|
/s/ David J. Drutz | |
| Name: | David J. Drutz | ||
| Title: | Chief Executive Officer | ||
SECURITIES AND EXCHANGE COMMISSION
Washington, DC
EXHIBITS
CURRENT REPORT
ON
FORM 8-K
|
Date of Event Reported:
|
Commission File No:
|
|
|
April 1, 2013
|
0-19410
|
DARA BIOSCIENCES, INC.
EXHIBIT INDEX
|
Exhibit No.
|
Exhibit Description
|
||
|
Press Release, dated April 1, 2013.
|
|||